<ARTICLE> 5 <LEGEND> THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE CONSOLIDATED BALANCE SHEET AS OF MARCH 31, 1996 AND CONSOLIDATED STATEMENT OF INCOME FOR THE THREE MONTHS ENDED MARCH 31, 1997 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS. </LEGEND> <MULTIPLIER> 1,000,000 <PERIOD-TYPE> 3-MOS <FISCAL-YEAR-END> DEC-31-1997 <PERIOD-START> JAN-01-1997 <PERIOD-END> MAR-31-1997 <CASH> 588 <SECURITIES> 0 <RECEIVABLES> 1,637 <ALLOWANCES> 32 <INVENTORY> 1,202 <CURRENT-ASSETS> 3,808 <PP&E> 4,075 <DEPRECIATION> 1,925 <TOTAL-ASSETS> 8,338 <CURRENT-LIABILITIES> 2,840 <BONDS> 2,174 <PREFERRED-MANDATORY> 0 <PREFERRED> 0 <COMMON> 288 <OTHER-SE> 2,038 <TOTAL-LIABILITY-AND-EQUITY> 8,338 <SALES> 1,443 <TOTAL-REVENUES> 1,443 <CGS> 782 <TOTAL-COSTS> 782 <OTHER-EXPENSES> 100<F1> <LOSS-PROVISION> 1 <INTEREST-EXPENSE> 47 <INCOME-PRETAX> (150) <INCOME-TAX> 53 <INCOME-CONTINUING> (203) <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> (203) <EPS-PRIMARY> (.74) <EPS-DILUTED> (.74)<F2> <FN> <F1> For "Other-Expenses" - Ref #5-03(0)3 - Includes R&D expense and goodwill amortization. <F2> For the three months ended 3/31/97, common stock equivalents were anti-dilutive. Consequently, "EPS, fully diluted" is shown without those common stock equivalents. </FN>